Human beings are big data. We aren’t just 175 pounds of meat and bone. We aren’t just piles of hydrogen and carbon and oxygen. What makes us all different is how it’s all organized and that is information. We can no longer treat people based on simple numbers like weight, pulse, blood pressure, and temperature. What makes us different is much more complicated than that. . . .
→ Read full post: Is Medicine a Big Data Problem?
Our portfolio company Assurex Health just announced the creation of a partnership with Canada’s Center for Addiction and Mental Health (CAMH), one of the world’s leading research centers in the area of addiction and mental health and Canada’s largest mental health teaching hospital. CAMH will offer to Canadian citizens the firm’s pharmacogenomic test, GeneSight, which is now widely available in the US. Claremont Creek Ventures is very excited about this step . . .
→ Read full post: Assurex Health Launches Collaboration with Canadian Mental Health Center
Our portfolio company NuMedii just announced a groundbreaking collaboration with Thomson Reuters, the world’s leading information provider for businesses. The Thomson Reuters Science division has quietly been aggregating an enormous database of biological, clinical, and pharmacological information over the past few years. As a biotech startup, NuMedii is focused on revolutionizing drug discovery by reducing the incredible inefficiencies and costs involved in small molecule drug development.
The drug development process is . . .
→ Read full post: Thomson Reuters and NuMedii Launch Initiative for Drug Discovery
Our portfolio company Assurex Health, announced recently the publication of a groundbreaking analysis of pharmacogenomic data in the International Review of Psychiatry.
The publication strongly validates the premise that the clinical use of genomic testing to help predict patient response to psychiatric medications significantly improves treatment outcomes. This is a key milestone in the continuing discussions within the Psychiatric community about the value of laboratory testing in . . .
→ Read full post: Assurex Health Publishes Seminal Paper on Pharmacogenomics
Our portfolio company Genalyte just announced the award of a government grant from the National Cancer Institute for the development of a diagnostic system using Genalyte’s proprietary biomarker technology (see Genalyte Expands into Cancer Profiling with $1 Million NCI Grant to Develop Cancer Biomarker Panel). This project is a significant validation of the company’s capability to assay blood biomarkers using the multiplex Maverick detection platform, which provides rapid, accurate, . . .
→ Read full post: Genalyte Receives National Cancer Institute Grant
Congratulations to our portfolio company NuMedii for a publication today in Cancer Discovery, which discusses the use of its technology by Stanford researchers to identify an antidepressant as a potential treatment for small cell lung cancer.
NuMedii is a pioneer in the future of pharmacology. As medicine becomes more personalized, every individual will get a custom treatment matched to their genetic and proteomic makeup and pathways. The old way of developing . . .
→ Read full post: Numedii discovers repurposed antidepressants have potential to treat small cell lung cancer
Earlier this week one of our portfolio companies, Genalyte, Inc., announced the release of a groundbreaking diagnostic system for early detection of Type 1 diabetes. This is of special significance to me as the young daughter of a good friend almost died due to undiagnosed Type 1 Diabetes – she was discovered by her parents in a low blood sugar coma in the middle of the night and rushed to . . .
→ Read full post: Genalyte and Colorado Diabetes Center Collaborate on Type 1 Diabetes
Top 5 pathways to personalized medicine
Healthcare IT NewsJeff RoweJuly 22, 2013
If there’s one thing everyone in healthcare can probably agree on right now, it’s that there is an awful lot of data being generated each and every day. What to do with that data, however, is another question.
As Ted Driscoll, digital health director at venture capital firm Claremont Creek Ventures, sees it, the explosion of data is a definite boon . . .
→ Read full post: Ted Driscoll interview in Health Care IT News “Top 5 pathways to personalized medicine”
Thursday June 20, 2013, Atul Butte, MD, PhD, a Stanford University Professor and entrepreneur is being honored at a formal ceremony in the White House Rose Garden in Washington DC. The Obama Administration is honoring Dr. Butte and several other genomics and molecular biology researchers who have focused on making large and complex sets of biological data open and widely accessible to the larger research community. Butte has been a leader . . .
→ Read full post: NuMedii Founder Atul Butte, MD, PhD honored at White House; Claremont Creek Ventures continues investment in health care Big Data.
Congratulations to Claremont Creek portfolio company Natera on closing a $54.6 million financing round. Given Claremont Creek Venture’s involvement since the company’s earliest round of financing, we know Natera is on its way to dominating the market for noninvasive, prenatal genetic testing. The financing is just the latest recent milestone for the company. In February it announced a major agreement with Quest Diagnostics, the world’s leading diagnostic information . . .
→ Read full post: Congratulations to Natera on Completing $54.6 Million Financing to Support Expansion